Investors are betting on biotech start-ups hitting the jackpot with innovative, high-demand medicines. Photo: Bloomberg

Chinese prostate, breast cancer drugs maker Kintor’s IPO more than 500 times oversubscribed as Hong Kong biotech investment fever continues

  • Kintor Pharmaceutical saw its HK$1.86 billion (US$240 million) IPO more than 500 times oversubscribed, said people familiar with the deal
  • It is the fifth biotech IPO sice December in Hong Kong to be massively oversubscribed as investors bet on start-ups hitting the jackpot with high-demand new medicines
Topic |   IPO
Investors are betting on biotech start-ups hitting the jackpot with innovative, high-demand medicines. Photo: Bloomberg
READ FULL ARTICLE